When a biotech company hits a wall—whether from clinical trial setbacks, market pressures, or strategic misalignment—one of the sharpest tools in a board’s hands is leadership change. Strategic leadership transitions can reset investor confidence, attract new talent, and redirect a company toward previously underexploited opportunities. Alvotech, a biosimilars manufacturer founded in 2013, exemplified this approach when it appointed Lisa Graver as Chief Executive Officer in January 2026, with founder Róbert Wessman transitioning to Executive Chairman by March 31, 2026. Graver brought 25+ years of pharmaceutical experience across generics, biosimilars, and branded drugs—skill sets that Wessman, while visionary as founder, had not prioritized in the role.
Leadership shifts in biotech are not cosmetic. They signal to investors that a company recognizes its problems and is willing to restructure at the top. BioNTech’s co-founders, Uğur Şahin and Özlem Türeci, announced in early 2026 that they would depart by year-end to establish a separate mRNA company with distinct operations and funding, while licensing next-generation technology back from BioNTech. Both cases demonstrate that struggling biotech ventures rarely fix themselves with the same people in the same roles.
Table of Contents
- When Does a Biotech Company Need New Leadership?
- The Complexity of Founder Transitions in Biotech
- Experience Requirements for Biotech Leadership Transitions
- How Investors Evaluate Leadership Changes
- The Risk of Institutional Drift During Leadership Handoffs
- Technology Transfer and Strategic Continuity
- Execution Timing and Stakeholder Management in Leadership Transitions
When Does a Biotech Company Need New Leadership?
Biotech companies face pressures that commodity manufacturers do not. A failed Phase 3 trial, regulatory rejection, or shift in the competitive landscape can invalidate a company’s entire value proposition overnight. Leadership transitions happen most often when current executives lack specific expertise for the new challenge ahead. At Alvotech, Graver’s prior role as CEO of Alvogen before its acquisition by Lotus Pharmaceutical Co. had given her intimate knowledge of how to scale biosimilar production and navigate regulatory approval with financial discipline—exactly what Alvotech needed as it matured beyond its founding vision.
Founders often excel at early-stage fundraising and vision-setting but may lack the operational rigor required to bring a drug to market profitably. Wessman founded Alvotech in 2013 and led it as CEO from 2023, but by 2026, the board recognized that Alvotech’s next phase—scaling manufacturing and executing Phase 3 trials under cost pressure—demanded different skills. this is not a failure of the founder; it is a function of how biotech companies evolve. The warning here is subtle: replacing a founder or long-serving CEO can alienate early investors and employees who bet on the original person. Boards must communicate clearly that the transition is not a vote of no-confidence in the company’s science, but rather an acknowledgment that managing a 300-person manufacturing operation is a different job than building one from 10 people.
The Complexity of Founder Transitions in Biotech
Founder-led companies carry tremendous accumulated knowledge in one or two people. When BioNTech’s co-founders announced their departure, the company’s stock price and partnerships were at stake. A poorly managed transition could trigger questions about whether BioNTech’s 15 ongoing Phase 3 oncology trials would stay on track. The binding agreement between BioNTech and the new company founded by Şahin and Türeci was not expected until end of June 2026—a deliberate timeline that preserved continuity while structuring the separation. The limitation that founders face is that their identity becomes inseparable from the company. Investors know Wessman as the person who spotted biosimilar opportunity in Iceland.
They know Şahin and Türeci as the researchers who built BioNTech’s mRNA platform from scratch. Transferring institutional knowledge to new leaders without losing that accumulated expertise is one of biotech’s hardest problems. Unlike a software company that can document architecture in a wiki, biotech expertise lives in networks of relationships, regulatory strategy, and unwritten manufacturing knowledge. Another constraint: founder departures often signal that the company has reached a different life stage, which can invite scrutiny from rivals and regulators. When a biotech founder steps back, people ask whether internal tensions created the change, whether upcoming data is unfavorable, or whether the company is being positioned for acquisition. The board must be prepared to defend the transition to regulators, patients in clinical trials, and existing partners who have contracts with the founder-led company.
Experience Requirements for Biotech Leadership Transitions
Biotech leadership is not interchangeable. A CEO from medical devices may not understand the regulatory pathway for a small-molecule drug. A venture capitalist with broad portfolio experience may not have navigated a Phase 3 trial. Graver’s appointment was not surprising in retrospect because her profile was specific: she had run a company through biosimilar approvals, managed manufacturing scale-up, and worked within the pricing pressures that biosimilar markets impose.
These are not generic CEO skills; they are biosimilar-specific. BioNTech’s situation was different because Şahin and Türeci were not being replaced by external hires—they were transitioning to a new venture. The risk was not a skills gap but rather institutional fracture: would the remaining BioNTech leadership, trained by the co-founders, maintain the same scientific standards and strategic coherence? BioNTech addressed this by creating a technology transfer agreement and establishing a timeline (contracts expiring before end of 2026) that gave the transition room to unfold without prolonged uncertainty. The practical detail: biotech boards often hire executives with prior regulatory approval experience because approvals are a critical path item. A company with a drug in Phase 2 can experiment with different organizational styles, but a company with a Phase 3 readout in 12 months cannot afford a CEO learning curve on FDA interactions.
How Investors Evaluate Leadership Changes
Investor response to biotech leadership changes follows a pattern. If the new hire’s résumé is credible and specific to the company’s next phase, investors often interpret the move positively—the board is being proactive, not reactive. When Graver joined Alvotech with prior board membership since 2022, investors saw continuity; she was not a stranger being parachuted in. She had observed the company’s operations and likely discussed the succession with the board before it was announced. In contrast, if a leadership change appears forced or arrives with minimal explanation, investors assume problems are being hidden. The company that announces a CEO departure on a Friday with a vague reason will face weeks of analyst questions and phone calls to board members.
BioNTech mitigated this by positioning the co-founders’ departure as a strategic choice—they were leaving to pursue new technology, not fleeing a sinking ship. The tradeoff is immediate: a company can use a leadership transition to reset expectations and buy time for new strategy to take hold, but the transition itself carries a cost. Key employees may leave during the vacuum. Partnerships may pause. Regulatory meetings may be rescheduled if a new CEO wants to represen the company’s position differently. This is why biotech boards time leadership changes carefully, often before bad news breaks rather than after.
The Risk of Institutional Drift During Leadership Handoffs
One overlooked risk in biotech leadership transitions is institutional drift. The company’s culture, decision-making style, and unwritten norms can shift between leaders. If Wessman’s era at Alvotech was marked by ambitious timelines and high risk tolerance, and Graver’s era emphasizes manufacturing reliability and cost control, employees face a new work environment. Some will thrive; others will leave. The company’s strategy may become more conservative, which is correct for a scaling manufacturing company but feels like retreat to people hired during the founder’s expansionist phase.
BioNTech’s situation creates a different drift risk: if Şahin and Türeci take their most innovative researchers to the new company, BioNTech’s remaining scientists may feel like they are stewarding a mature platform rather than pioneering next-generation therapy. The binding agreement and technology transfer help, but they cannot guarantee that the best talent will stay. This is a warning for biotech boards considering founder departures: star scientists and operators often follow the founder, not the company. The limitation here is that boards cannot fully control culture drift. They can hire carefully and communicate vision, but institutional change is largely emergent—the sum of many decisions by employees, not a controlled variable.
Technology Transfer and Strategic Continuity
When founders depart, technology transfer becomes critical. BioNTech’s agreement to license next-generation mRNA innovations to the co-founders’ new company was not charity; it was strategic. BioNTech retains the right to use the technology while allowing Şahin and Türeci to pursue parallel R&D. This avoids a winner-take-all situation where the new company either becomes a threat or dies without resources.
It also gives BioNTech’s remaining leadership and investors confidence that the transition will not hollow out the company’s competitive moat. Alvotech’s transition did not involve technology transfer because Wessman was moving to Chairman, not leaving the company entirely. His knowledge of Alvotech’s manufacturing processes, regulatory strategy, and partnership networks remained accessible, but day-to-day decision-making was handed to Graver. This hybrid model—founder as Chairman, new CEO executing—is common in mature biotech when founders want to stay involved without being the bottleneck.
Execution Timing and Stakeholder Management in Leadership Transitions
Biotech leadership transitions must be coordinated across multiple audiences simultaneously: employees, investors, regulators, patients in clinical trials, and board members with competing interests. Alvotech set a clear deadline—Wessman would transition by March 31, 2026—which gave Graver time to embed before major regulatory or clinical events. BioNTech structured its co-founder departure timeline to align with contract expiration dates by end of 2026, creating a natural boundary rather than an abrupt handoff. The concrete execution detail: Graver had been on Alvotech’s Board since 2022 before being elevated to CEO.
This meant she had institutional knowledge, existing relationships with board members and key executives, and credibility with investors who had voted for her on the board. The company did not have to onboard a complete outsider; it was promoting and rebalancing someone already embedded. By contrast, when biotech companies hire CEOs from outside without board tenure, the first 90 days are often turbulent as the new leader learns the organization, regulatory status, and financial pressures simultaneously. Alvotech avoided this by promoting from within.